Donepezil, Anti-Alzheimer’s Disease Drug, Prevents Cardiac Rupture during Acute Phase of Myocardial Infarction in Mice
by Mikihiko Arikawa, Yoshihiko Kakinuma, Takemi Handa, Fumiyasu Yamasaki, Takayuki Sato
We have previously demonstrated that the chronic intervention in the cholinergic system by donepezil, an acetylcholinesterase inhibitor, plays a beneficial role in suppressing long-term cardiac remodeling after myocardial infarction (MI). In comparison with such a chronic effect, however, the acute effect of donepezil during an acute phase of MI remains unclear. Noticing recent findings of a cholinergic mechanism for anti-inflammatory actions, we tested the hypothesis that donepezil attenuates an acute inflammatory tissue injury following MI.
Methods and Results
In isolated and activated macrophages, donepezil significantly reduced intra- and extracellular matrix metalloproteinase-9 (MMP-9). In mice with MI, despite the comparable values of heart rate and blood pressure, the donepezil-treated group showed a significantly lower incidence of cardiac rupture than the untreated group during the acute phase of MI. Immunohistochemistry revealed that MMP-9 was localized at the infarct area where a large number of inflammatory cells including macrophages infiltrated, and the expression and the enzymatic activity of MMP-9 at the left ventricular infarct area was significantly reduced in the donepezil-treated group.
The present study suggests that donepezil inhibits the MMP-9-related acute inflammatory tissue injury in the infarcted myocardium, thereby reduces the risk of left ventricular free wall rupture during the acute phase of MI.
For the full article visit: Donepezil, Anti-Alzheimer’s Disease Drug, Prevents Cardiac Rupture during Acute Phase of Myocardial Infarction in Mice
Syndicated from:PLoS ONE
Article is licensed under a Creative Commons Attribution License.